Literature DB >> 21606158

Protein expression and fucosylated glycans of the serum haptoglobin-{beta} subunit in hepatitis B virus-based liver diseases.

Hong Shu1, Shu Zhang, Xiaonan Kang, Shan Li, Xue Qin, Chun Sun, Haojie Lu, Yinkun Liu.   

Abstract

Glycosylation, which regulates the configuration and function of glycoproteins, is the most important post-translational modification. The aim of this study was to observe the differential patterns in glycan and protein parts of the serum haptoglobin-β subunit (Hp-β) purified from patients with hepatitis B virus (HBV) infection, liver cirrhosis (LC), or hepatocellular carcinoma (HCC). 2-D gel electrophoresis and multiplexed proteomics staining technique were employed to investigate whether the Hp-β glycan level was proportional to the protein level. Multi-lectin blot, high-performance liquid chromatography (HPLC), and western blot analysis were carried out to identify the glycoform of Hp-β quantitatively. Our experiments showed that the ratio of total serum Hp-β to the glycosylated form of Hp-β varied among the patients with different liver diseases. The total Hp-β protein expression level was much higher in HCC than LC, while an incremental proportion of fucosylated Hp-β was also observed in LC and HCC patients compared with that in HBV and healthy controls. Differential fucosylation was further identified as a Lewis X structure by HPLC and anti-human Sialyl-Lewis X antibody. In conclusion, the aberrant alternation of Hp-β glycan and total protein expression may be a promising biomarker for early hepatocarcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21606158     DOI: 10.1093/abbs/gmr038

Source DB:  PubMed          Journal:  Acta Biochim Biophys Sin (Shanghai)        ISSN: 1672-9145            Impact factor:   3.848


  7 in total

Review 1.  Proteins and Proteoforms: New Separation Challenges.

Authors:  Fred E Regnier; JinHee Kim
Journal:  Anal Chem       Date:  2017-12-18       Impact factor: 6.986

2.  PRM-MS Quantitative Analysis of Isomeric N-Glycopeptides Derived from Human Serum Haptoglobin of Patients with Cirrhosis and Hepatocellular Carcinoma.

Authors:  Cristian D Gutierrez Reyes; Yifan Huang; Mojgan Atashi; Jie Zhang; Jianhui Zhu; Suyu Liu; Neehar D Parikh; Amit G Singal; Jianliang Dai; David M Lubman; Yehia Mechref
Journal:  Metabolites       Date:  2021-08-23

3.  Site-specific glycoforms of haptoglobin in liver cirrhosis and hepatocellular carcinoma.

Authors:  Petr Pompach; Zuzana Brnakova; Miloslav Sanda; Jing Wu; Nathan Edwards; Radoslav Goldman
Journal:  Mol Cell Proteomics       Date:  2013-02-06       Impact factor: 5.911

4.  Temozolomide-induced increase of tumorigenicity can be diminished by targeting of mitochondria in in vitro models of patient individual glioblastoma.

Authors:  Doreen William; Madlin Walther; Björn Schneider; Michael Linnebacher; Carl Friedrich Classen
Journal:  PLoS One       Date:  2018-01-19       Impact factor: 3.240

5.  Aided Diagnosis of Hepatocellular Carcinoma Using Serum Fucosylated Haptoglobin Ratios.

Authors:  Shuxin Shang; Wei Li; Xue Qin; Shu Zhang; Yinkun Liu
Journal:  J Cancer       Date:  2017-03-07       Impact factor: 4.207

6.  FUT family mediates the multidrug resistance of human hepatocellular carcinoma via the PI3K/Akt signaling pathway.

Authors:  L Cheng; S Luo; C Jin; H Ma; H Zhou; L Jia
Journal:  Cell Death Dis       Date:  2013-11-14       Impact factor: 8.469

7.  Quantification of Intact O-Glycopeptides on Haptoglobin in Sera of Patients With Hepatocellular Carcinoma and Liver Cirrhosis.

Authors:  Hong Shu; Lei Zhang; Yiwei Chen; Yijie Guo; Limin Li; Fanghua Chen; Zhao Cao; Guoquan Yan; Chunlai Lu; Chao Liu; Shu Zhang
Journal:  Front Chem       Date:  2021-07-14       Impact factor: 5.221

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.